Commercial Insight: Migraine - A Painful Future for the Triptans?

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2004-12-22

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Although migraine market revenues have demonstrated almost 12% growth over the last four years across the seven major pharmaceutical markets reaching approximately $2.4 billion in 2003, growth is predicted to slow as the market becomes increasingly crowded.


Scope

  • Overview of current market including profiles of key brands and key events impacting each brand during 2003-2004
  • Assessment of current and future opportunities and threats in the migraine market across the seven major pharmaceutical markets
  • Global sales for leading migraine products are presented, with projections for future performance up to 2014
  • In-depth discussion of assumptions and events used in forecast analysis


    • Report Highlights
    First-line therapy predominantly utilizes simple analgesics and NSAIDs, despite the lack of sustained anti-migraine effect seen with these products and the risk of rebound headaches. Commercial growth of the triptan class has the potential to be accelerated by encouraging wider and earlier use through patient and PCP education.

    Increasing use of preventative treatments will drive future market expansion. Of current drug classes, the anticonvulsants are projected to benefit from this trend, while prophylactic use of triptans is expected to be limited to menstrually associated migraine (MAM) over the forecast period.

    As patent expiries take effect on the market, it is likely that the focus on the cost of therapies will increase. Consistent physician valued differentiation between the oral triptans is currently poor, which, if left unchecked, will lead to significant cross-brand erosion following the launch of generic sumatriptan.


    Reasons to Purchase

  • Quantify future size and scope of the migraine market and potential for new products
  • Understand key drivers to this market and predict future performance of these compounds
  • Identify hot areas of the market not targeted by competitors

    • Table of Contents

    Other users found this report page using the following search terms: migraine headache migraine triptan market triptans generic sumatriptan topamax patent migrainea zolmitriptan

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.